Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael A. Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin T. Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood blood.2024026212.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Holly Lee, Michael Durante, Sungwoo Ahn, Noemie Leblay, Mansour Poorebrahim, Ranjan Maity, Rémi Tilmont, Elie Barakat, David Jung, Bachisio Ziccheddu, Alexis Brake, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2023-188080

Published: 2023

Journal Articles

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Holly Lee, Sungwoo Ahn, Ranjan Maity, Noémie Leblay, Michael Durante, Bachisio Ziccheddu, Alexis Brake, Remi Tilmont, Elie Barakat, Mansour Poorebrahim, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2023-190517

Published: 2023

Journal Articles

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Blood (2023) 142 (Supplement 1): 3764.

https://doi.org/10.1182/blood-2023-190882

Published: 2023

Journal Articles

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Francesco Maura, Marcella Kaddoura, Alexandra Maria Poos, Anthony Cirrincione, Benjamin Diamond, Kylee H Maclachlan, Bachisio Ziccheddu, Elias K. Mai, Hartmut Goldschmidt, Katja Weisel, Roland Fenk, Gareth J. Morgan, Saad Z Usmani, Ola Landgren, Marc S. Raab, Niels Weinhold

Blood (2023) 142 (Supplement 1): 638.

https://doi.org/10.1182/blood-2023-182267

Published: 2023

Journal Articles

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Blood (2023) 142 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2023-190473

Published: 2023

Journal Articles

Clinical Impact of Neoantigen Burden and HLA Loss in Aggressive B-Cell Lymphomas Treated with CD19 CAR T-Cell

Bachisio Ziccheddu, Michael D. Jain, Monika Chojnacka, Michael Durante, Julieta Abraham Miranda, Meghan Menges, Ola Landgren, Marco Davila, Jonathan H. Schatz, Francesco Maura, Frederick L. Locke

Blood (2023) 142 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2023-182821

Published: 2023

Journal Articles

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

Blood (2023) 142 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2023-189316

Published: 2023

Journal Articles

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Benjamin Diamond, Niccolò Bolli, Paolo Corradini, David Coffey, Ola Landgren, Benedetto Bruno, Mario Boccadoro, Massimo Massaia, Francesco Maura, Alessandra Larocca

Blood (2023) 142 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2023-182301

Published: 2023

Journal Articles

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Mark B Meads, Kylee H Maclachlan, Saad Z Usmani, Marc S. Raab, Gareth J. Morgan, Niels Weinhold, Kenneth H. Shain, Ola Landgren, Francesco Maura

Blood (2023) 142 (Supplement 1): 639.

https://doi.org/10.1182/blood-2023-184784

Published: 2023

Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 874.

https://doi.org/10.1182/blood-2023-186802

Published: 2023

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

Holly Lee, Paola Neri, Sungwoo Ahn, Ranjan Maity, Noemie Leblay, Bachisio Ziccheddu, Monika Chojnacka, Rémi Tilmont, Elie Barakat, Ola Landgren, Francesco Maura, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 252–253.

https://doi.org/10.1182/blood-2022-167602

Published: 2022

Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Blood (2022) 140 (Supplement 1): 430–432.

https://doi.org/10.1182/blood-2022-167390

Published: 2022

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Blood (2022) 140 (Supplement 1): 2088–2090.

https://doi.org/10.1182/blood-2022-158992

Published: 2022

Journal Articles

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Blood (2022) 140 (Supplement 1): 1137–1139.

https://doi.org/10.1182/blood-2022-160308

Published: 2022

NARROW

Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Clinical Impact of Neoantigen Burden and HLA Loss in Aggressive B-Cell Lymphomas Treated with CD19 CAR T-Cell

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only